FOXP3 and B-cell chronic lymphocytic leukemia: This did not seem to be the case in the FOXP3+ subset from some patients treated with ibrutinib, as their pSTAT5 levels were much higher than in HCs and untreated patients with advanced CLL (Figure 5H,I).